Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Xenon Pharmaceuticals (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company, has granted equity inducements to six new non-officer employees totaling 24,750 share options. The options were granted on June 23, 2025, with an exercise price of $31.49 per common share, matching the closing price on the grant date.
The share options have a four-year vesting schedule, with 25% vesting after one year and the remaining vesting monthly over three years. Each option has a 10-year term and is subject to the company's 2025 Inducement Equity Incentive Plan.
Xenon Pharmaceuticals (Nasdaq: XENE), un'azienda biofarmaceutica specializzata in neuroscienze, ha concesso incentivi azionari a sei nuovi dipendenti non dirigenti per un totale di 24.750 opzioni su azioni. Le opzioni sono state assegnate il 23 giugno 2025, con un prezzo di esercizio di 31,49 $ per azione ordinaria, pari al prezzo di chiusura del giorno della concessione.
Le opzioni hanno un piano di maturazione quadriennale, con il 25% che matura dopo un anno e il resto che matura mensilmente nei successivi tre anni. Ogni opzione ha una durata di 10 anni ed è soggetta al Piano di Incentivi Azionari 2025 dell'azienda.
Xenon Pharmaceuticals (Nasdaq: XENE), una compañía biofarmacéutica enfocada en neurociencia, ha otorgado incentivos accionarios a seis nuevos empleados no ejecutivos por un total de 24,750 opciones sobre acciones. Las opciones fueron concedidas el 23 de junio de 2025, con un precio de ejercicio de $31.49 por acción común, igualando el precio de cierre en la fecha de concesión.
Las opciones tienen un programa de adquisición de derechos de cuatro años, con un 25% que se adquiere después de un año y el resto que se adquiere mensualmente durante los siguientes tres años. Cada opción tiene un plazo de 10 años y está sujeta al Plan de Incentivos de Capital 2025 de la compañía.
Xenon Pharmaceuticals (나스닥: XENE)는 신경과학에 중점을 둔 바이오제약 회사로서, 6명의 신규 비임원 직원에게 총 24,750주 주식매수선택권을 부여했습니다. 이 옵션은 2025년 6월 23일에 부여되었으며, 행사 가격은 주당 31.49달러로 부여일 종가와 동일합니다.
주식매수선택권은 4년간 권리 취득 일정을 가지며, 1년 후 25%가 취득되고 나머지는 3년 동안 매월 취득됩니다. 각 옵션은 10년 만기이며 회사의 2025년 유인 주식 인센티브 계획에 따릅니다.
Xenon Pharmaceuticals (Nasdaq : XENE), une société biopharmaceutique spécialisée en neurosciences, a accordé des incitations en actions à six nouveaux employés non cadres pour un total de 24 750 options d'achat d'actions. Les options ont été attribuées le 23 juin 2025, avec un prix d'exercice de 31,49 $ par action ordinaire, correspondant au cours de clôture à la date d'attribution.
Les options d'achat ont un calendrier d'acquisition sur quatre ans, avec 25 % acquises après un an et le reste acquis mensuellement sur les trois années suivantes. Chaque option a une durée de 10 ans et est soumise au Plan d'Incitation en Actions 2025 de la société.
Xenon Pharmaceuticals (Nasdaq: XENE), ein biopharmazeutisches Unternehmen mit Schwerpunkt Neurowissenschaften, hat sechs neue Mitarbeiter ohne leitende Funktion mit insgesamt 24.750 Aktienoptionen ausgestattet. Die Optionen wurden am 23. Juni 2025 gewährt, mit einem Ausübungspreis von 31,49 $ pro Stammaktie, entsprechend dem Schlusskurs am Tag der Gewährung.
Die Aktienoptionen unterliegen einem vierjährigen Vesting-Plan, wobei 25 % nach einem Jahr und der Rest monatlich über die folgenden drei Jahre freigegeben wird. Jede Option hat eine 10-jährige Laufzeit und unterliegt dem Aktienanreizplan 2025 des Unternehmens.
- None.
- None.
VANCOUVER, British Columbia and BOSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to six new non-officer employees consisting of an aggregate of 24,750 share options. All of the foregoing share options were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of June 23, 2025 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of
About Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics. We are advancing an ion channel product portfolio to address areas of high unmet medical need, including epilepsy and depression. Azetukalner, a novel, highly potent, selective Kv7 potassium channel opener, represents the most advanced, clinically validated potassium channel modulator in late-stage clinical development for multiple indications. For more information, please visit www.xenon-pharma.com.
“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.
Contacts:
For Investors:
Chad Fugere
Vice President, Investor Relations
(857) 675-7275
investors@xenon-pharma.com
For Media:
Colleen Alabiso
Senior Vice President, Corporate Affairs
(617) 671-9238
media@xenon-pharma.com
FAQ
What equity inducement grants did Xenon Pharmaceuticals (XENE) announce on June 26, 2025?
What is the vesting schedule for XENE's new employee stock options?
What is the exercise price for Xenon Pharmaceuticals' June 2025 inducement grants?
How long is the term for XENE's June 2025 inducement stock options?
